Caprock Group’s Celldex Therapeutics CLDX Stock Holding History

Caprock Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-904	Closed	-$32K	–	450
2018 Q1	$32K	Buy	+904	New	+$35K	0.01%	443

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Caprock Group's CLDX Position: Q2 2018 in Review

Caprock Group sold out of Celldex Therapeutics (CLDX) in Q2 2018, closing a stake of 904 shares — an estimated $32K sold.

Caprock Group first reported a position in CLDX in Q1 2018 and held it in 1 quarter. The position peaked at $32K in Q1 2018. 102 funds tracked by Wall St. Rank hold CLDX as of Q2 2018.

Caprock Group reported no remaining Celldex Therapeutics position as of Q2 2018 after selling out during the quarter.
Caprock Group sold 904 Celldex Therapeutics shares in Q2 2018, an estimated $32K.
Caprock Group first reported a position in Celldex Therapeutics in Q1 2018 and held it in 1 quarter.
Caprock Group's Celldex Therapeutics position peaked at $32K in Q1 2018.
102 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2018.

Based on Caprock Group's 13F filing for Q2 2018, filed 23 Jul 2018.